u03c5u03c0u03bfu03bau03b1u03c4u03b5u03c3u03c4u03b7u03bcu03b5u03bdu03b5u03c2u82b3u57fau5316u5408u7269u7684u03b9u03bdu03b4u03bfu03bbu03bfu548cu03bcu03b5u03c4u03b1u03b2u03bfu03bbu03b9u03c4u03b5u03c2u03bau03c5u03bdu03bfu03c5u03c1u03b5u03bdu03b9u03bdu03b7u03c2/u03bcu03b5u03c4u03b1u03b2u03bfu03bbu03b9u03c4u03b5u03c2u03bau03c5u03bdu03bfu03c5u03c1u03b1u03bcu03b9u03bdu03b7u4f5cu4e3au4ed6u4eecu7684u8fd9u4e9bu03b8u03b5u03c1u03b1u03c0u03b5u03c5u03c4u03b9u03bau03bfu03b9u56e0u7d20

摘要

The present invention is a group of substituted alkyl aryl compounds, of which a group of related characteristics are characterized by different PI p_delta e__________, These compositions and medicines are manufactured in the presence of the metabolites of kappa Rho/ metabolites and similar factors These compounds.The present invention provides further guidance for the regulation of N-methyl D-alpha____channels by drugs on GSK3 beta kinase inhibitors and/or Delta p__channels. (NMDA) for the treatment of neurodegeneration and other diseases.